Insight Molecular Diagnostics Inc (IMDX)

Apr 20, 2026

Major Investor Makes Bold Move Into Insight Molecular Diagnostics - TipRanks

Apr 20, 2026

Apr 20, 2026

Broadwood Partners buys $652,875 in Insight Molecular Diagnostics By Investing.com - Investing.com South Africa

Apr 20, 2026

Apr 20, 2026

Broadwood Partners buys $652,875 in Insight Molecular Diagnostics - Investing.com

Apr 20, 2026

Apr 20, 2026

Broadwood boosts Insight Molecular (IMDX) stake with 182,861-share buy - Stock Titan

Apr 20, 2026

Apr 20, 2026

Insight (IMDX) Stock Range-Bound (Marginal Loss) 2026-04-20Gap Down Stocks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 20, 2026

Apr 17, 2026

Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛

Apr 17, 2026

Apr 16, 2026

Stock List: Research Stocks from Around the World - GuruFocus

Apr 16, 2026

Apr 15, 2026

IMDX: GraftAssure's decentralized PCR test drives transplant diagnostics innovation and market expansion - TradingView

Apr 15, 2026

Apr 15, 2026

IMDX: GraftAssure aims to transform transplant diagnostics with decentralized, high-margin testing - TradingView — Track All Markets

Apr 15, 2026

Apr 15, 2026

Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay - marketscreener.com

Apr 15, 2026

Apr 14, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 14, 2026

Apr 14, 2026

Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay - GlobeNewswire

Apr 14, 2026

Apr 14, 2026

Kidney transplant test data heads to 3 global medical meetings - Stock Titan

Apr 14, 2026

Apr 13, 2026

Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst - Yahoo Finance

Apr 13, 2026

Apr 11, 2026

IMDX Options Volatility — NASDAQ:IMDX - TradingView

Apr 11, 2026

Apr 11, 2026

IMDX Options Chain — NASDAQ:IMDX - TradingView

Apr 11, 2026

Apr 10, 2026

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Apr 10, 2026

Apr 10, 2026

Capital expenditures of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView

Apr 10, 2026

Apr 07, 2026

IMDX Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 07, 2026

Apr 07, 2026

Insight Molecular Diagnostics Inc. Stock Forecast Summary - Meyka

Apr 07, 2026

Apr 01, 2026

BTIG reiterates Neutral rating on Insight Molecular stock By Investing.com - Investing.com Canada

Apr 01, 2026

Apr 01, 2026

BTIG reiterates Neutral rating on Insight Molecular stock - Investing.com

Apr 01, 2026

Mar 31, 2026

Insight Molecular (IMDX) Soars 22.36% During Intraday Rally — What’s Driving the Market Turbulence? - Bitget

Mar 31, 2026

Mar 31, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Mar 31, 2026

Mar 30, 2026

IMDX CFO’s RSUs Vest as Company Withholds Shares for Taxes - Stock Titan

Mar 30, 2026

Mar 30, 2026

IMDX (IMDX) VP Yang sees RSUs vest while shares withheld for taxes - Stock Titan

Mar 30, 2026

Mar 30, 2026

CEO at Insight Molecular (IMDX) vests 47,170 RSUs with no share sale - Stock Titan

Mar 30, 2026

Mar 30, 2026

Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com

Mar 30, 2026

Mar 30, 2026

Trade Insight Molecular Diagnostics IncOCX CFD - Capital.com

Mar 30, 2026

Mar 30, 2026

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 30, 2026

Mar 29, 2026

How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst - Yahoo! Finance Canada

Mar 29, 2026

Mar 27, 2026

Insight Molecular Diagnostics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 27, 2026

Mar 27, 2026

Needham reiterates Buy on Insight Molecular stock, $9 target By Investing.com - Investing.com India

Mar 27, 2026

Mar 27, 2026

Insight Molecular Diagnostics Inc. Q4 2025 earnings preview - MSN

Mar 27, 2026

Mar 27, 2026

Needham reiterates Buy on Insight Molecular stock, $9 target - Investing.com

Mar 27, 2026

Mar 26, 2026

Insight Molecular Diagnostics outlines $2B annual market opportunity and signals rapid commercialization push for GraftAssureDx - MSN

Mar 26, 2026

Mar 26, 2026

Earnings call transcript: Insight Molecular Diagnostics Q4 2025 reveals strategic milestones - Investing.com India

Mar 26, 2026

Mar 26, 2026

Insight Molecular Diagnostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2026

Mar 26, 2026

Insight Molecular Diagnostics (NASDAQ:IMDX) Soars on 285% Revenue Beat and Key FDA Submission - ChartMill

Mar 26, 2026

Mar 26, 2026

Insight Molecular Diagnostics: Q4 Earnings Snapshot - crossville-chronicle.com

Mar 26, 2026

Mar 26, 2026

IMDX: Revenue doubled and net loss narrowed as focus shifted to transplant diagnostics and kit commercialization - TradingView

Mar 26, 2026

Mar 26, 2026

IMDX: FDA submission of GraftAssureDx and strong clinical data set stage for 2026 commercialization - TradingView

Mar 26, 2026

Mar 26, 2026

IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results - The Manila Times

Mar 26, 2026

Mar 26, 2026

Insight Molecular 2025 10-K: Revenue $4.06M, Net Loss $50.22M - TradingView

Mar 26, 2026

Mar 26, 2026

Insight Molecular Diagnostics posts Q4 2025 results; revenue $1.1M in quarter, $4.1M full year - TradingView

Mar 26, 2026

Mar 26, 2026

Insight Molecular Diagnostics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener

Mar 26, 2026

Mar 26, 2026

Insight Molecular Diagnostics (IMDX) files GraftAssureDx with FDA and reports 2025 loss - Stock Titan

Mar 26, 2026